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Background: Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. Several hospitals throughout
the region provide primary treatment for these patients and it is well know that treatment quality is correlated to
the hospital that delivers. The aim of this study was to investigate the management and treatment of EOC in a
Region of the North Italy (Emilia-Romagna, Italy).
Methods: A multidisciplinary group made up of 11 physicians and 3 biostatisticians was formed in 2009 to perform
clinical audits in order to identify quality indicators and to develop Region-wide workup in accordance with the
principles of evidence-based medicine (EBM). The rationale was that, by setting up an oncogynecology network so
as to achieve the best clinical practice, critical points would decrease or even be eliminated. Analysis of cases was
based on the review of the medical records.
Results: 614 EOC patients treated between 2007 and 2008 were identified. We found only 2 high-volume hospitals
(≥ 21 patients/year), 3 medium-volume hospitals (11–20 operated patients/year), and 7 low-volume hospitals
(≤ 10 operated patients /year). Only 222 patients (76.3%) had a histological diagnosis, FIGO surgical staging was
reported only in 206 patients (70.9%) but not all standard surgical procedures were always performed, residual
disease were not reported in all patients. No standard number of neoadjuvant chemotherapy cycles
was observed.
Conclusions: The differences in terms of treatments provided led the multidisciplinary group to identify reference
centers, to promote centralization, to ensure uniform and adequate treatment to patients treated in regional centers
and to promote a new audit involving all regional hospitals to a complete review of the all the EOC patients.
Keywords: Epithelial ovarian cancer, Centralized care, Clinical audit, Quality of care, Guide lineBackground
Epithelial ovarian cancer (EOC) is the most lethal
gynecological cancer. Worldwide, there are 224,747 new
cases yearly and an estimated 140,163 disease-related
deaths [1]. In Europe, approximately 66,700 new ovarian
cancer cases are diagnosed yearly, with the highest inci-
dence in the Northern European countries and the United* Correspondence: dariomandato@virgilio.it
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reproduction in any medium, provided the orKingdom [2,3]. The lifetime risk varies from 1.1 to 1.6 in
Europe and the United States (US) [4]. The majority of
women (about 65%) are diagnosed at advanced Inter-
national Federation of Obstetricians and Gynecologists
(FIGO) stage (III-IV) 5-year survival is only 48.8% of all
the patients, and the median overall survival is 24 months.
However, the 5-year-survival rate varies widely among
European countries, from 25.6% to 51.4% [5,6].
In the Emilia-Romagna Region, a region of the North
Italy, there is a yearly average of 17.6 new EOC per
100,000 females (about 401 new cases); 40 hospitalsal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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these patients. The 5-year survival rate is 39.4% (36.4-
42.4, CI 95%), with about 319 disease-related deaths
every year.
For ovarian cancer patients, the chance of surviving de-
pends both on unchangeable variables such as patient
characteristics and tumor biology and on modifiable vari-
ables such as quality of treatment (surgical treatment,
chemotherapy). Because treatment quality is correlated
to the hospital that delivers it and because high-volume
hospitals provide a better prognosis, centralizing care for
ovarian cancer patients is now recommended [7,8]. In light
of this recommendation, we decided to investigate the
management and treatment of EOC in Emilia-Romagna.
To this end, a multidisciplinary group was formed in 2009,
and trained to perform clinical audits in order to identify
quality indicators and to develop Region-wide workup
in accordance with the principles of evidence-based
medicine (EBM). The rationale was that, by setting up
an oncogynecology network so as to achieve the best
clinical practice, critical points would decrease or even
be eliminated.
To the best of our knowledge, this is the first Italian
regional audit whose aim is to assess the quality of care
of EOC patients [9].
Methods
Study design
In 2009, 11 physicians and 3 biostatisticians whose goal
was to set up an oncologic network named Rete di
oncologia ginecologica della Regione Emilia-Romagna
(ROGER).
A preparatory scoping audit was undertaken to iden-
tify the key issues involved in the management of EOC.
Quality and standard indicators for improvement were
identified after a careful revision of the literature and of
the leading gynecologic societies’ guidelines (GL).
Were identified as quality and standard indicators
in the diagnostic and therapeutic strategy of EOC:
modality of diagnosis, washing/cytology, hysterectomy,
salpingoophorectomy, omentectomy, appendectomy,
peritoneal biopsy, pelvic and lumbo-aortic lymphade-
nectomy, peritonectomy, bowel resection, cholecystec-
tomy, splenectomy, residual disease, chemotherapy, and
hospital volume.
Clinical audit was organized in three phases. Firstly, pa-
tients treated in the period from 2007 to 2008 were retro-
spectively analyzed. Secondly, to evaluate further the
quality of the ovarian cancer treatment, patients treated
from 2009 to 2010 were also included in the analysis. Due
to the failure to adhere to all 40 hospitals, it was not pos-
sible to review the data records but to evaluate all cases in
the region, the analysis was based on the regional current
data base. Thirdly, region-wide GL (RGL) were drafted toidentify reference centers, promote centralization, pro-
mote teaching, and to ensure uniform and adequate treat-
ment to patients treated in regional centers.
Case ascertainment and data collection
All the patients with histological and/or cytological and/or
radiological diagnosis of EOC in Emilia-Romagna hospi-
tals were included in the audit. Patients were identified
using the International Classification of Diseases, 9th Revi-
sion, Clinical Modification (ICD-IX-CM) code for malig-
nant ovarian cancer (cod. 183.0) by means of record
linkage between data from hospital discharge records and
from pathological database.
Each of the engaged physicians formed a team to
evaluate cases from that particular hospital. Data were
registered on a website designed for that purpose. The
case report form included all the information necessary
to evaluate the quality indicators.
Hospitals were divided in low volume (≤ 10 cases per
year), medium volume (between 11 and 20 cases per year)
and high volume (≥21 cases per year) and data were
analysed according to the volume.
Data handling and analysis
Data were exported electronically from the website into
SAS (version 9.2; SAS Institute Inc., Cary, NC, US). The
Web data entry ensured that few data were missing for
clinical cases included in the analysis. Multiple compari-
sons were made between presenting characteristics and
principal clinical outcomes of patients.
Statistical methods
Patient data were presented as percentages and summary
statistics of mean and standard deviation, where appropri-
ate. In order to identify significant changes in clinical prac-
tice, a statistical univariate analysis was performed using,
as appropriate, χ2-test, Fisher’s exact test, and Tukey’s test
to evaluate the different distribution of the type of treat-
ment, residual disease and cases volume, analysis of vari-
ance (ANOVA) test (Snedecor’s F test) and Student’s t test
to evaluate mean age differences by treatment, and
Kaplan-Meier curves and the log-rank test for survival
analysis. A Cox proportional hazard regression model was
used for multivariate analyses to study the effects of
teaching hospitals, volume of hospitals and of age (dependent
variable) on survival (undependent variable).
The differences observed were statistically significant
for a p value less than 0.05.
SAS was used for all data analyses.
Results
Forty hospitals that had treated at least one case of EOC
in the period under study were identified. Based on
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2007 and 2008 were identified.
A detailed analysis was based on the review of the
medical records. Between 2007 and 2008, 1,071 cases
were identified throughout the Emilia Romagna Region,
of these 614 (57.3%) patients were treated in hospitals
participated in the audit. Two hundred and ninety-one
(27.2%) medical records were included in the final ana-
lysis, whereas 223 (20.8%) cases were not included in the
review because on review of the medical records, the pa-
tients were affected also other cancer or because it was
not possible to be sure of the diagnosis.
The EOC patients had an age of 63.7 ± 16.5 (years ± SD).
Two (20%) high volume, three (30%) medium volume
and five (50%) low volume hospitals were identified.
Of 291 patients only 134 patients (46%) were treated in
the high volume hospitals.
Staging was available for 248 of the 291 patients
(85.2%): 50 (20.2%), 15 (6%), 131 (52.8%) and 52 (21.0%)
patients were at stage I, II, III, and IV, respectively. A
similar number of early stage (I-II) and advanced stage
(III-IV) patients were treated in low-, medium- and
high-volume hospitals (p = 0.23). Specifically, 28 (41.2%),
20 (29.4%) and 20 (29.4%) early stage patients were
treated in high-, medium-, and low-volume hospitals, re-
spectively. Similarly, 66 (47.8%), 46 (33.3%), and 26
(18,8%) advanced stage patients were treated in high-,
medium-, and low-volume hospitals, respectively.
Two hundred and twenty-two (76.3%) patients had a
histological diagnosis, 29 (9.9%) had a cytological diag-
nosis, and 28 (9.6%) had only a radiological diagnosis;
the method of diagnosis was not reported for 12 (4.1%)
patients. There were 116 patients (39.9%) with serous
EOC, 32 (10.9%) patients with undifferentiated EOC, 22
(7.6%) with endometrioid EOC, 15 (5.1%) with mucinous
EOC, 14 (4.8%) with clear cell EOC, and 33 (11.3%) with
other hystotypes. Histotype was not reported in 59
patients (20.3%).
Survival of the 291 EOC patients according to the
treatments is reported in Table 1.Table 1 Survival of the 291 EOC patients treated between 20
the type of treatment
Only
surgery
Only chemo
therapy
Neo adjuvant c
surgery + chem
Follow-up N. % N. % N.
Dead 16 30.2 21 46.7 9
Live with disease 1 1.9 6 13.3 12
Live free of disease 31 58.5 3 6.7 13
No data 5 9.4 15 33.3 6
Total 53 100 45 100 40In the early stages (I-II), complete staging was not al-
ways performed and lumbo-aortic lymphadenectomy was
performed only in 35% of patients (Table 2). Residual dis-
ease at first cytoreduction surgery was not reported in
30% of patients. A complete cytoreduction was obtained
only in 20.1% of patients with stage III-IV (Table 2).
Only chemotherapy was administered to 45 (15.5%) pa-
tients (years ± SD, 68.8 ± 16.8), with an average of 4.8 cycles
(range 1–11 cycles). Neoadjuvant chemotherapy was ad-
ministered to 40 (13.7%) patients (years ± SD, 60.4 ± 14.6),
with an average of 5.1 cycles (range 1–8 cycles). Adjuvant
chemotherapy was administered to 123 (42.3%) patients
(years ± SD, 59.9 ± 11.4), with an average of 5.6 cycles
(range 1–8 cycles). Although high volume hospitals
presented the higher overall survival compared with low
and medium volume hospitals, these differences were
not significant. Survival according to stage is reported
in Table 2.
On the basis of the first set of results (2007–2008), it
became clear that further evaluation would require in-
cluding all patients treated in the whole region even in
those hospitals which have not adhered to the audit. To
do this, current regional data base was analyzed without
reviewing data records. Based on ICD-IX-CM codes,
2163 EOC patients treated between 2007–2010 were
thus identified (Table 3). Based on the number of treated
patients, we found 2 (5%) high-volume hospitals (≥ 21
operated patients /year), 5 (12.5%) medium-volume hos-
pitals (11–20 operated patients/year), and 33 (82.5%)
low-volume hospitals (≤10 operated patients /year). Of
these 40 hospitals, five (12.5%) were teaching hospitals.
Median survival was 30 months.
The distribution of patients according to treatment is
shown in Table 3 and type of first treatment according to
age is reported in Table 4. When dividing the patients
according to age, it was found that the majority of patients
(63.18%) aged >70 years received only supportive care.
Type of first treatment according to hospital volume
showed significant differences. In low-volume hospitals,
significantly (p < 0.0001) fewer patients (43%) were surgi-
cally treated than were in medium- (54.8%) and high-
volume (69.1%) hospitals and significantly (p < 0.0001)07–2008 at four years from first treatment according to
hemotherapy +
otherapy
Surgery + adjuvant
chemotherapy
Supportive
care
% N. % N. %
22.5 20 16.3 30 0
30 31 25.2 0 0
32.5 46 37.4 0 0
15 26 21.1 0 0
100 123 100 30 100
Table 2 Characteristics of the 206 EOC patients surgically
treated between 2007-2008
Stage I Stage II Stage III-IV
Mean age (years ± SD) 55.6 ± 15.6 56.5 ±10.6 63.6 ± 13.0
N. % N. % N. %
Surgical procedures
Washing 41 87.2 11 73.3 70 48.6
Hysterectomy 40 85.1 15 100 96 66.7
Annessiectomy 47 100.0 15 100 144 100
Omentectomy 41 87.2 15 100.0 91 63.2
Appendectomy 21 44.7 6 40.0 30 20.8
Peritoneal biopsy 33 70.2 11 73.3 70 48.6
Pelvic lymphadenectomy 20 42.6 10 66.7 49 34.0
Lumbo-aortic lymphadenectomy 17 36.2 5 33.3 33 22.9
Peritonectomy 3 6.4 1 6.7 25 17.4
Colecistectomy 1 2.1 0 0.0 5 3.5
Bowel resection 0 0 0 0 20 13.9
Splenectomy 0 0 0 0 4 2.8
Total 47 15 144
Residual disease
Not reported 17 36.2 8 53.3 37 25.7
No residual disease 28 59.6 7 46.7 29 20.1
<=1 cm 0 0.0 0 0.0 7 4.9
> = 2 cm 0 0.0 0 0.0 23 16.0
Residual disease present but
the diameter is not specified
0 0.0 0 0.0 16 11.1
Missing 2 4.3 0 0 32 22.2
Total 47 100 15 100 144 100
Survival at four years
from surgically treatment
Live free of disease 36 76.6 6 40.0 37 25.7
Dead 0 0.0 2 13.3 44 30.6
Live with disease 3 6.4 4 26.7 39 27.1
No data 8 17.0 3 20.0 24 16.7
Total 47 100 15 100 144 100
Type of treatment
Only surgery 24 46.8 - - 8 5.6%
Surgery plus adjuvant
chemotherapy
22 51.1 14 93.3 74 51.4%
Neo adjuvant chemotherapy
plus surgery plus chemotherapy
1 2.1 1 6.7 35 24.3%
Only chemotherapy - - - - 24 16.7%
Supportive care - - - - 3 2.1%
Total 47 100 15 100 144 100
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than were in high-volume (4.8%) but similar to the num-
ber in medium-volume hospitals (10.1%). Further, signifi-
cantly (p < 0.0001) more patients (44.1%) in low-volume
hospitals received no treatment than did those in
medium- (35.1%) and high-volume (26.1%) hospitals
(Figure 1a).
A significantly greater number of patients treated at
teaching hospitals (5 hospitals) received surgery as first
treatment compared to those treated in non-teaching hos-
pitals (35 hospitals) (59.7% vs. 47.7%, respectively; p <
0.0001). Teaching and non-teaching hospitals treated a
similar number of cases with chemotherapy (8.5% vs.
11.5%, respectively, p = 0.0289) but teaching hospitals of-
fered supportive care to a significantly lower number of
cases compared with non-teaching hospitals (31.8% vs.
40.9% respectively, p < 0.0001) (Figure 1b).
Patients treated in the high-volume hospitals presented
a significantly lower risk of dying compared to patients
treated in medium- and low-volume hospitals. Patients
treated in teaching hospitals presented a significantly
lower risk of dying compared with patients treated in non-
teaching hospitals (Figure 2). Women aged ≤64 years
showed a statistically higher survival compared to women
aged ≥ 65 years (3.756 years and 2.273 years, respectively,
p < 0.0001).
Hospital volume correlation with patient age was sta-
tistically significant (p < 0.0001): 52.4% of the women
treated in high volume hospital were aged ≤ 64 years,
44.7% of those treated in medium volume hospital were
aged ≤ 64 years, and 39.8% of those treated in low vol-
ume hospital were aged ≤ 64 years.
Multivariate analysis showed that lower volume hospital
(compared to high) increased the risk of lower survival
and that it increased slightly in not-teaching hospitalsTable 3 Characteristics of the 2163 EOC patients treated
between 2007-2010
Age Total
2007 2008 2009 2010
N. % N. % N. % N. % N
< 40 years 33 6.3 33 6.1 35 6.2 26 4.9 127
40 – 55 years 97 18.4 98 18.0 112 19.8 97 18.4 404
55 – 69 years 172 32.7 182 33.4 182 32.2 166 31.6 702
> 70 years 224 42.6 232 42.6 237 41.9 237 45.1 930
Total 526 100 545 100 566 100 526 100 2163
Treatment N. % N. % N. % N. % N
Chemo -therapy 46 8.7 59 10.8 56 9.9 63 12.0 224
Surgery 269 51.1 273 50.1 310 54.8 275 52.3 1.127
No treatment 211 40.1 213 39.1 200 35.3 188 35.7 812
Total 526 100 545 100 566 100 526 100 2163
Table 4 Type of first treatment according to the age of the 2163 EOC patients treated between 2007-2010
AGE Total
< 40 years 40 – 55 years 55 – 69 years > 70 years
N. % N. % N. % N. % N
Chemotherapy 9 4.0 38 17.0 84 37.5 93 41.5 224
Surgery 99 8.8 296 26.3 408 36.2 324 28.7 1.127
No treatment 19 2.3 70 8.6 210 25.9 513 63.2 812
Total 127 5.9 404 18.7 702 32.5 930 43.0 2163
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ated with survival, with women older than 65 years having
an increased risk of lower survival (HR 2.86) compared to
younger women.
Discussion
Despite several improvements in the treatment of EOC,
this malignancy remains the leading cause of the death
among gynecologic tumors [10].Figure 1 Type of first treatment according to the patients volume (a)To the best of our knowledge, the present study is the
first Italian regional audit whose goal was to assess the
current state of where and how treatment of EOC is pro-
vided in Emilia-Romagna Region and to determine the ap-
propriateness of its diagnostic and treatment pathway. To
this end, a regional oncology network (ROGER) was formed
whose aim was to improve EOC patient outcomes by ensur-
ing uniformity of care and treatment. The audit reviewed
EOC cases treated in the period 2007–2008, discoveringand to the teaching (b) hospitals.
Figure 2 Risk of death in the 2,163 EOC patients according to the patients volume (a) and to the teaching of the hospital.
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for review, only 222 patients (76.3%) had a histological diag-
nosis, FIGO surgical staging was reported only in 206 pa-
tients (70.9%) but not all standard surgical procedures were
always performed, however the 70% of the patients were at
advanced FIGO stage (Table 2).
It is unacceptable that patients for whom no reliable
histological diagnosis and staging is available are treated
without proven indication to the chemotherapy. Yet our
audit indicated that this may have occurred.
While our audit brought to light some very troubling and
serious lapses in diagnosis and treatment, similar scenarios
reported in the literature show that the Emilia-Romagna re-
gion is not alone. To this regard, in 2003, the Advanced
Chemotherapy in Ovarian Neoplasm (ACTION) trial re-
ported that inadequate staging affected the outcome of the
trial (only 34% of the FIGO stage I-IIA patients were
staged), despite the fact that strict staging guidelines had
been given [9-14]. Probably the omission of staging wasdue to the lack of surgical expertise in fact it occurred more
frequently at institutions that had enrolled fewer than five
patients. However, only 37% of patients even from institu-
tions entering >20 patients were completely staged. Similar
findings were reported in the Surveillance, Epidemiology
and End Results Program study [15-17].
Today, the aim of surgery in ovarian cancer is the
complete resection of the tumor [18-20]. Our audit
showed that only 20.1% of advanced-stage patients under-
went complete cytoreduction, with a further 30.1% of the
patients for whom this parameter was not reported, des-
pite it is the most important prognostic factor and quality
indicator of the surgery [21]. Recent studies have con-
firmed that surgical outcome depends on the surgeon and
hospital-related factors rather than on the spreading
pattern of the tumor [17,22].
A greater diversity of treatment was also observed in
the administration of neoadjuvant chemotherapy; the
median number of cycles administered to the patients
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of chemotherapy are usually suggested; more would
delay cytoreductive surgery, resulting in potentially det-
rimental effects on the survival in advanced EOC [12].
Given these critical findings for 2007–2008, we felt that
a larger-scale evaluation was opportune and thus extended
the audit to include all the EOC patients treated in the
whole region 2009–2010 as well.
Considering all the EOC patients treated from 2007 to
2010, only the 26.8% of EOC patients underwent surgery
in the high-volume hospitals. In the 2 high-volume hospi-
tals 69.1% of the patients underwent surgery as primary
treatment; surgery represented primary treatment also in
the 59.7% of the patients of the five teaching hospitals.
These findings are not surprising, given that in the
Regional Healthcare System of Emilia Romagna there is
no centralization for EOC patients.
Above all, in line with the literature, regardless of
stage, the patients treated in the high-volume hospitals
presented a significantly lower risk of death compared with
patients treated in medium- and low-volume hospitals re-
gardless of patient age and structure (teaching or not
teaching). Patients treated in teaching hospitals presented a
significantly lower risk of dying compared with patients
treated in non-teaching hospitals. This finding emerged
despite the fact that the majority (but not statistically
significant) of advanced stages were operated in high-
volume hospitals.
However, it must be emphasized that the patients
treated in the medium and low volume hospitals were
progressively and significantly older than those treated
in the high volume hospitals and that the age proved to
be strongly related to lower survival in multivariate ana-
lysis. The older patients may have had a lower survival
for several reasons, including the coexistence of other pre-
existing diseases or the surgeon’s propensity to limit sur-
gery in elderly patients with comorbidities. These findings
are in accordance with the literature, where it is reported
that elderly women with EOC are less likely to be central-
ized and to undergo surgery by an oncogynecologist [23].
However, results from the current regional data base are
weakened because they were not on reviewed data records,
so these data should not to be over interpret, but they rep-
resent a preliminary analysis.
Over the last decade, several studies have reported the im-
portance of centralizing care of ovarian cancer patients to
guarantee the assistance of specialized gynecologists, thereby
improving prognosis/ survival [7-11]. It is discouraging to
see that our regional findings are not much better than
those reported in a national Italian audit performed in 1988,
after national guidelines were provided by the National Re-
search Council . That analysis showed serious deficiencies in
diagnostic and staging procedures and information on grad-
ing and residual tumour was available only in 30% and 45%of cases, respectively, and only 10% of the patients had
random biopsies as part of their surgical staging [24].
The differences between hospitals in terms of treatments
provided and the differences between the treatments pro-
vided and the gold standard led the multidisciplinary
group to draft standardized Regional GL (RGL) to identify
reference centers, to promote centralization, and to ensure
uniform and adequate treatment to patients treated in
regional centers [25].Conclusion
Despite we reviewed only the 47.4% of the EOC cases
treated in period 2007–2008, our audit has played a pivotal
role in assessing the quality of regional assistance and in
highlighting critical points such as the inconsistent ap-
proach to care and the failure to apply international GL.
This audit has allowed us to perform a preliminary analysis
of how, where, when, and by whom EOC is treated in
regional hospitals. These results are a wake-up call tense
that should push all professionals in the region to take part
in a future audit for a more rigorous effort for a more ac-
curate assessment of all patients treated in the region.
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